Видео ютуба по тегу Tecelra

Adrian Rawcliffe, Adaptimmune 🇬🇧 | Tecelra, TCR Cell Therapy, Solid Tumors | E22
Adrian Rawcliffe, Adaptimmune 🇬🇧 | Tecelra, TCR Cell Therapy, Solid Tumors | E22
Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma
Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma
FDA approves first non CAR T cell therapy for solid tumors!
FDA approves first non CAR T cell therapy for solid tumors!
Breakthrough in Cancer Care: Tecelra's FDA Approval Changes Everything!
Breakthrough in Cancer Care: Tecelra's FDA Approval Changes Everything!
Irving Ford on Leading Adaptimmune through the FDA approval and commercialisation of Tecelra.
Irving Ford on Leading Adaptimmune through the FDA approval and commercialisation of Tecelra.
FDA Approves First Gene Therapy for Adult Metastatic Synovial Sarcoma!
FDA Approves First Gene Therapy for Adult Metastatic Synovial Sarcoma!
Adaptimmune SPEAR T-Cell Mechanism of Action Video
Adaptimmune SPEAR T-Cell Mechanism of Action Video
FDA D.I.S.C.O. Burst Edition: FDA approval of Tecelra (afamitresgene autoleucel) for unresectable...
FDA D.I.S.C.O. Burst Edition: FDA approval of Tecelra (afamitresgene autoleucel) for unresectable...
Adaptimmune Therapeutics plc (ADAP)
Adaptimmune Therapeutics plc (ADAP)
[MediRama EDGE] Tecelra BLA by 메디라마 CEO 문한림
[MediRama EDGE] Tecelra BLA by 메디라마 CEO 문한림
Smart Cell Therapies for Solid Cancers
Smart Cell Therapies for Solid Cancers
What is CAR T-Cell Therapy? What Cancer Patients NEED to Know!
What is CAR T-Cell Therapy? What Cancer Patients NEED to Know!
What’s Next For Adaptimmune?
What’s Next For Adaptimmune?
Adaptimmune’s Adrian Rawcliffe On Changing Our Relationship With Cancer
Adaptimmune’s Adrian Rawcliffe On Changing Our Relationship With Cancer
💰 What's Next for Adaptimmune ($ADAP) After Selling its Star Drug?
💰 What's Next for Adaptimmune ($ADAP) After Selling its Star Drug?
Annual Colby's Path 5K raises awareness of synovial sarcoma
Annual Colby's Path 5K raises awareness of synovial sarcoma
Cell Therapies that Can Do a Solid for People with Cancer
Cell Therapies that Can Do a Solid for People with Cancer
Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams
Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams
Adaptimmune (ADAP|$451.6M) - 2025 Q1 Earnings Analysis
Adaptimmune (ADAP|$451.6M) - 2025 Q1 Earnings Analysis